COMP <GO>
NRIX vs BHC // RETURN ON INVESTED CAPITAL (ROIC)
Nurix Therapeutics Inc. (NASDAQ) VS. Bausch Health Companies Inc. (NYSE) • 15-METRIC TALLY: NRIX 2
— BHC 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: BHC
LAST: $25.70 (-4.10%) • MKT CAP: $2.93B
roic
-35.00%
LAST: $8.02 (-2.19%) • MKT CAP: $3.07B
roic
7.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRIX VS. BHC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NRIX | BHC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 7.60% | -42.60 | BHC | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 10.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.89% | 22.00% | -30.89 | BHC | /fcf-yield <GO> |
| Operating Margin | -60.00% | 17.70% | -77.70 | BHC | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 1.50% | -61.50 | BHC | /net-margins <GO> |
| Revenue Growth (YoY) | 54.00% | 6.70% | +47.30 | NRIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.52 | 0.45 | +9.07 | NRIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | BHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.3 | 64.8 | -2.50 | BHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.97 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 19.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.93B | $3.07B | -$141.1M | BHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NRIX REV | BHC REV | NRIX GROSS % | BHC GROSS % | NRIX FCF | BHC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $84.0M | $10.27B | — | — | -$263.5M | $1.00B |
| FY 2024 | $54.5M | $9.63B | — | — | -$181.9M | $1.26B |
| FY 2023 | $77.0M | $8.76B | — | — | -$81.4M | $637.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRIX // BETA —
BHC // BETA 0.97